AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8596376 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 39393 (10 mg)
Number of subjects: 1119
Study 8596376 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 39393 (15 mg)
Number of subjects: 1119
Study 8596376 — intervention group
Group type: EXPERIMENTAL
Intervention: CGP 39393 (20 mg)
Number of subjects: 1119
Study 8596376 — intervention group
Group type: COMPARATOR
Intervention: Heparin (5000 IU three times daily)
Number of subjects: 1119
Study 1822255 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (bolus dose 10 micrograms x kg‐1 followed by a constant-rate infusion of 0.02 microgram x kg‐1 x min‐1)
Number of subjects: 9
Study 1822255 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of atropine (approximately 1.8‐1.9 mg)
Number of subjects: 9
Study 1822255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1822255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholinergic blockade
Number of subjects: 9
Study 7077022 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I ('helped') - extensive assistance in completing the task
Number of subjects: 72
Study 7077022 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II ('encouraged only') - verbal encouragement but minimal assistance
Number of subjects: 72
Study 7077022 — intervention group
Group type: COMPARATOR
Intervention: Group III ('no contact') - control group with no training sessions
Number of subjects: 72
Study 7077022 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I ('helped')
Number of subjects: 72
Study 7077022 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II ('encouraged only')
Number of subjects: 72
Study 29688760 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-enriched multivitamin
Number of subjects: 73
Study 29688760 — intervention group
Group type: COMPARATOR
Intervention: Control multivitamin without antioxidant enrichment
Number of subjects: 73
Study 27352882 — intervention group
Group type: EXPERIMENTAL
Intervention: Melbourne InFANT Program intervention promoting recommended feeding practices
Number of subjects: 542
Study 25232265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliva prebiotic (0.5-2 ounces diluted in ORS)
Number of subjects: 300
Study 25232265 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliva prebiotic
Number of subjects: 300
Study 25232265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 ounces diluted in ORS)
Number of subjects: 300
Study 22309507 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% 0.4 ml · kg(‐1) plus clonidine 1 μg · kg(‐1) in 1 ml (RC)
Number of subjects: 60
Study 22309507 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2% 0.4 ml · kg(‐1) plus saline in 1 ml (RS)
Number of subjects: 60
Study 20235224 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 5604
Study 20235224 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 5604
Study 20235224 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 5604
Study 20235224 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers and cardiac glycosides
Number of subjects: 5604
Study 20235224 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 5604
Study 20235224 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 5604
Study 20235224 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone or Sotalol
Number of subjects: 5604
Study 17667496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/min infusion for 4 hours postoperatively)
Number of subjects: 60
Study 17667496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 60
Study 17667496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16148557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral norfloxacin (25 patients)
Number of subjects: 94
Study 16148557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin/sulbactam (21 patients)
Number of subjects: 94
Study 16148557 — intervention group
Group type: COMPARATOR
Intervention: Cirrhotic patients with variceal bleeding
Number of subjects: 94
Study 16148557 — intervention group
Group type: COMPARATOR
Intervention: Cirrhotic patients admitted for other reasons
Number of subjects: 94
Study 12166344 — intervention group
Group type: EXPERIMENTAL
Intervention: Niceritrol 750‐1500 mg/day + Pravastatin 10 mg/day (after 8 weeks)
Number of subjects: 62
Study 12166344 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 10 mg/day + Niceritrol 750‐1500 mg/day (after 8 weeks)
Number of subjects: 62
Study 12166344 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Niceritrol + Pravastatin)
Number of subjects: 62
Study 12166344 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin alone
Number of subjects: 62
Study 9565385 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal recommendation from one of the investigators
Number of subjects: 445
Study 9565385 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation plus an easy‐to‐read National Cancer Institute (NCI) brochure
Number of subjects: 445
Study 9565385 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation, brochure, and a 12‐minute interactive educational and motivational program
Number of subjects: 445
Study 9565385 — intervention group
Group type: COMPARATOR
Intervention: Recommendation alone
Number of subjects: 445
Study 9565385 — intervention group
Group type: COMPARATOR
Intervention: Recommendation with brochure
Number of subjects: 445
Study 8292907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocos nucifera pollen extract immunotherapy (CPE‐IT)
Number of subjects: 96
Study 8292907 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 96
Study 3052814 — intervention group
Group type: COMPARATOR
Intervention: d-fenfluramine (30 mg/day)
Number of subjects: 0
Study 3052814 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine (single dose of 0, 30, 40, and 60 mg)
Number of subjects: 0
Study 3052814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29297195 — intervention group
Group type: EXPERIMENTAL
Intervention: CPRMeter (feedback group)
Number of subjects: 50
Study 29297195 — intervention group
Group type: COMPARATOR
Intervention: Standard non-feedback CPR (non-feedback group)
Number of subjects: 50
Study 27356644 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 45
Study 27356644 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 45
Study 27356644 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 45
Study 27356644 — intervention group
Group type: EXPERIMENTAL
Intervention: Treg (Regulatory cells) in all sedation groups (midazolam, propofol, dexmedetomidine)
Number of subjects: 45
Study 27356644 — intervention group
Group type: COMPARATOR
Intervention: Treg after 3 ICU days in dexmedetomidine group
Number of subjects: 45
Study 27356644 — intervention group
Group type: COMPARATOR
Intervention: Treg after 5 ICU days in propofol group
Number of subjects: 45
Study 27356644 — intervention group
Group type: COMPARATOR
Intervention: Treg after 5 ICU days in midazolam group
Number of subjects: 45
Study 24796047 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Taichong (LR 3), Zusanli (ST 36), and Sanyinjiao (SP 6), once a day, 5 times per week for 4 weeks
Number of subjects: 57
Study 24796047 — intervention group
Group type: COMPARATOR
Intervention: Medication group treated with pinaverium (50 mg, 3 times a day) and live combined bifidobacterium and lactobacillus tablet (4 tablets, 3 times a day) for 4 weeks
Number of subjects: 57
Study 22621163 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper™ Single Bond Plus (SB)
Number of subjects: 97
Study 22621163 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper™ Scotchbond SE (SE)
Number of subjects: 97
Study 22621163 — intervention group
Group type: EXPERIMENTAL
Intervention: Both adhesive systems (SB and SE)
Number of subjects: 97
Study 20418692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative duration of low BIS (BIS < 45)
Number of subjects: 460
Study 20418692 — intervention group
Group type: COMPARATOR
Intervention: Volatile anesthetic concentration
Number of subjects: 460
Study 18208917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (n=13)
Number of subjects: 50
Study 18208917 — intervention group
Group type: COMPARATOR
Intervention: Opioids (n=24)
Number of subjects: 50
Study 18208917 — intervention group
Group type: COMPARATOR
Intervention: Non-opioid analgesics (n=13)
Number of subjects: 50
Study 15870609 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 17
Study 15870609 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% + Pilocarpine (2%, 4%, 6%)
Number of subjects: 17
Study 15870609 — intervention group
Group type: COMPARATOR
Intervention: Pilocarpine (2%, 4%, 6%)
Number of subjects: 17
Study 12697633 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem, 1 g once a day
Number of subjects: 1167
Study 12697633 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam, 3.375 g every 6 h
Number of subjects: 1167
Study 12697633 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone, 1 g once a day
Number of subjects: 1167
Study 12536743 — intervention group
Group type: COMPARATOR
Intervention: FU (1 mg.kg‐1) combination with sham infusion
Number of subjects: 18
Study 12536743 — intervention group
Group type: EXPERIMENTAL
Intervention: FU (1 mg.kg‐1) combination with 50 ml of 20% solution of Albumin
Number of subjects: 18
Study 12536743 — intervention group
Group type: EXPERIMENTAL
Intervention: FU (1 mg/kg) combination with 250 ml dextran 40
Number of subjects: 18
Study 12536743 — intervention group
Group type: EXPERIMENTAL
Intervention: FU (1 mg.kg‐1) combination with Albumin
Number of subjects: 18
Study 12536743 — intervention group
Group type: EXPERIMENTAL
Intervention: FU (1 mg/kg) combination with dextran 40
Number of subjects: 18
Study 9154895 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 ppm ozone for 2 hours
Number of subjects: 12
Study 9154895 — intervention group
Group type: COMPARATOR
Intervention: Filtered air for 2 hours
Number of subjects: 12
Study 8355942 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream 2% (5 g intravaginally at bedtime for 7 days)
Number of subjects: 407
Study 8355942 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 500 mg (two 250-mg capsules orally twice a day for 7 days)
Number of subjects: 407
Study 8355942 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin vaginal cream 2%
Number of subjects: 407
Study 8355942 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 500 mg
Number of subjects: 407
Study 3549923 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of berberine sulfate (BS) in a single oral dose for ETEC diarrhea
Number of subjects: 165
Study 3549923 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of berberine sulfate (BS) for ETEC diarrhea
Number of subjects: 165
Study 3549923 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of berberine sulfate (BS) for cholera
Number of subjects: 165
Study 3549923 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg of berberine sulfate (BS) plus tetracycline for cholera
Number of subjects: 165
Study 2473883 — intervention group
Group type: EXPERIMENTAL
Intervention: New pocket-size ambulatory monitor for detecting spike and wave episodes
Number of subjects: 11
Study 2473883 — intervention group
Group type: COMPARATOR
Intervention: Double-blind trial with independent scoring by 2 experienced encephalographers
Number of subjects: 11
Study 31828956 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-interval (≤7 weeks)
Number of subjects: 157
Study 31828956 — intervention group
Group type: COMPARATOR
Intervention: Long-interval (>7 weeks)
Number of subjects: 157
Study 30167954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilaprazole 20 mg daily for 8 weeks
Number of subjects: 176
Study 30167954 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 20 mg daily for 8 weeks
Number of subjects: 176
Study 27793818 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin and oral ciprofloxacin for 3 days
Number of subjects: 300
Study 27793818 — intervention group
Group type: COMPARATOR
Intervention: Oral ciprofloxacin and oral cefuroxime for 3 days
Number of subjects: 300
Study 26501119 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygiene information provided to CMV-seronegative women
Number of subjects: 646
Study 26501119 — intervention group
Group type: COMPARATOR
Intervention: No hygiene information provided (comparison group)
Number of subjects: 646
Study 23303870 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-fortified rice (n = 101)
Number of subjects: 203
Study 23303870 — intervention group
Group type: COMPARATOR
Intervention: Natural control rice (n = 102)
Number of subjects: 203
Study 20805775 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope (AWS) with Manual Inline Stabilization (MIS)
Number of subjects: 30
Study 20805775 — intervention group
Group type: COMPARATOR
Intervention: Airway Scope (AWS) with cervical collar immobilization
Number of subjects: 30
Study 19640524 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge needle
Number of subjects: 131
Study 19640524 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-gauge needle
Number of subjects: 131
Study 19640524 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 131
Study 17348452 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome 18q allelic imbalance (AI) present
Number of subjects: 280
Study 17348452 — intervention group
Group type: COMPARATOR
Intervention: No chromosome 18q allelic imbalance (AI)
Number of subjects: 280
Study 15983311 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based care management
Number of subjects: 104
Study 15983311 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study 11148512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (IB) 250 microg combined with 2.5 mg albuterol by jet nebulization.
Number of subjects: 210
Study 11148512 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (IB) for children >6 years (N = 70).
Number of subjects: 210
Study 11148512 — intervention group
Group type: COMPARATOR
Intervention: Placebo group received isotonic saline solution substituted for IB.
Number of subjects: 210
Study 9351559 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening
Number of subjects: 30000
Study 9351559 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA in combination with digital rectal examination
Number of subjects: 30000
Study 7513718 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-h iv GH infusion (1 IU/h)
Number of subjects: 14
Study 7513718 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day sc GH treatment (8 IU/day) followed by 12-h iv infusion of GH (1 IU/h)
Number of subjects: 14
Study 7513718 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular daily sc GH therapy (3 IU/m2.day)
Number of subjects: 14
Study 7513718 — intervention group
Group type: COMPARATOR
Intervention: 12-h iv saline infusion
Number of subjects: 14
Study 7513718 — intervention group
Group type: COMPARATOR
Intervention: No GH (after discontinuation of GH for 2 days)
Number of subjects: 14
Study 3284975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 238
Study 3284975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) plus fluoxymesterone (FLU)
Number of subjects: 238
Study 3284975 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxymesterone (FLU) following TAM
Number of subjects: 238
Study 30683087 — intervention group
Group type: EXPERIMENTAL
Intervention: Training package for tobacco cessation support for TB health workers (interactive two-day training)
Number of subjects: 36
Study 30683087 — intervention group
Group type: EXPERIMENTAL
Intervention: COM-B questionnaire administered to TB health workers
Number of subjects: 36
Study 27840330 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (30 mg IV bolus and 1 mg/kg subcutaneous dose)
Number of subjects: 25
Study 27840330 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 25
Study 27840330 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 25
Study 25724860 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized colistin 1 million IU twice a day for one year
Number of subjects: 39
Study 25724860 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 39
Study 25724860 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized colistin
Number of subjects: 39
Study 23012159 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered secondary prevention program
Number of subjects: 430
Study 23012159 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 430
Study 21952357 — intervention group
Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 94
Study 21952357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 18334782 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (7.5 mg/ml)
Number of subjects: 20
Study 18334782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% without an additive
Number of subjects: 20
Study 18334782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% with an adrenaline additive (1:200,000)
Number of subjects: 20
Study 18334782 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution (placebo)
Number of subjects: 20
Study 16551149 — intervention group
Group type: EXPERIMENTAL
Intervention: Family therapy
Number of subjects: 100
Study 16551149 — intervention group
Group type: COMPARATOR
Intervention: Individual cognitive-behavioral therapy (CBT)
Number of subjects: 100
Study 15153823 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1 compression stockings (10‐15 mmHg at the ankle)
Number of subjects: 125
Study 15153823 — intervention group
Group type: COMPARATOR
Intervention: Reference stockings of identical appearance
Number of subjects: 125
Study 15153823 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1 compression stockings
Number of subjects: 125
Study 10984373 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide nasal spray
Number of subjects: 30
Study 10984373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10984373 — intervention group
Group type: COMPARATOR
Intervention: Budesonide nasal spray and Placebo
Number of subjects: 30
Study 8799514 — intervention group
Group type: COMPARATOR
Intervention: 619C89 (0.5, 1, 1.5, 2, 2.5 mg kg‐1 loading infusions followed by 0.25, 0.5, 0.75, 1, 1.25 mg kg‐1 maintenance infusions)
Number of subjects: 48
Study 8799514 — intervention group
Group type: COMPARATOR
Intervention: 619C89
Number of subjects: 48
Study 1847648 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with cyclophosphamide (10 G m‐2), ifosfamide (11 G m‐2), mitomycin C (70 mg m‐2), mustine (30 mg m‐2)
Number of subjects: 23
Study 1847648 — intervention group
Group type: COMPARATOR
Intervention: High dose chemotherapy with cisplatin (100 mg m‐2), ifosfamide (11 G m‐2), mitomycin C (70 mg m‐2), mustine (30 mg m‐2)
Number of subjects: 23
Study 6335905 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Gla-protein (BGP) levels in LT-ROD patients
Number of subjects: 30
Study 6335905 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Gla-protein (BGP) levels in HT-ROD patients
Number of subjects: 30
Study 6335905 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of BGP with parathyroid hormone
Number of subjects: 30
Study 6335905 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of BGP with alkaline phosphatase
Number of subjects: 30
Study 6335905 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of BGP with cellular and non-cellular parameters of bone formation
Number of subjects: 30
Study 6335905 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of BGP with histologic parameters of bone
Number of subjects: 30
Study 31462554 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop NA therapy for 72 weeks
Number of subjects: 67
Study 31462554 — intervention group
Group type: COMPARATOR
Intervention: Continue NA therapy for 72 weeks
Number of subjects: 67
Study 31462554 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop NA therapy
Number of subjects: 67
Study 31462554 — intervention group
Group type: COMPARATOR
Intervention: Continue NA therapy
Number of subjects: 67
Study 31462554 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study 30150460 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg MEDI8852 plus 75 mg oseltamivir
Number of subjects: 126
Study 30150460 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000 mg MEDI8852 plus 75 mg oseltamivir
Number of subjects: 126
Study 30150460 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,000 mg MEDI8852 alone
Number of subjects: 126
Study 30150460 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 75 mg oseltamivir
Number of subjects: 126
Study 30150460 — intervention group
Group type: EXPERIMENTAL
Intervention: All MEDI8852 cohorts combined
Number of subjects: 126
Study 30150460 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir only (cohort 3)
Number of subjects: 126
Study 27793183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (COG)
Number of subjects: 80
Study 27793183 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise training (PE)
Number of subjects: 80
Study 27793183 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential training (SEQ)
Number of subjects: 80
Study 27793183 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training (DUAL)
Number of subjects: 80
Study 25297614 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g/d L-tryptophan
Number of subjects: 17
Study 25297614 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g/d L-tryptophan
Number of subjects: 17
Study 25297614 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g/d L-tryptophan
Number of subjects: 17
Study 25297614 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 g/d L-tryptophan
Number of subjects: 17
Study 25297614 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 g/d L-tryptophan
Number of subjects: 17